Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a [15% plunge in Lilly’s shares]( ...